Jessica S. Estriplet

FDA investigator

Appears on 18 documents from 2021 to 2026, most often at sites in New Jersey. Most often cites responsibilities of quality control unit (21 CFR 211.22).

18
Documents on file
4.4
Observations per 483
2021
First seen
2026
Most recent

What they cite most

From 80 observations

Activity by year

2021: 1, 2022: 4, 2023: 4, 2024: 1, 2025: 5, 2026: 3

Where

New Jersey 8 · India 4 · Canada 2 · Japan 2 · Pennsylvania 2

Is Jessica S. Estriplet coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

18 documents, newest first
FirmOpen
483 Emcure Pharmaceuticals LimitedMay 15, 2026 · Ahmedabad, India
483 Zydus Lifesciences LimitedMay 5, 2026 · Ahmedabad, India
483 Atlantic Analytical Laboratories LLCMar 17, 2026 · Whitehouse, New Jersey
483 MSN Laboratories Private Limited Unit-05, Sy. Nos. (Parts of)7,8,13 andDec 11, 2025 · Farooqnagar Mandal, India
Amended 483 Sumitomo Dainippon Pharma Co., Ltd.Jul 11, 2025 · Oita, Japan
483 Shionogi Pharma Co., Ltd.Jul 1, 2025 · Kanegasaki, Japan
483 Everest Life Sciences LLCApr 23, 2025 · PLAINSBORO, New Jersey

About this profile

What does Jessica S. Estriplet inspect?

Jessica S. Estriplet appears on 18 documents on file covering 17 sites, most often in New Jersey.

What do they cite most often?

21 CFR 211.22 (responsibilities of quality control unit), followed by 21 CFR 211.68 and 21 CFR 211.100.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Jessica S. Estriplet is dated May 15, 2026.